{
    "nctId": "NCT05594082",
    "briefTitle": "Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer",
    "officialTitle": "Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer.",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients aged over 18 years old.\n2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.\n3. Plan to receive or has received Trastuzumab Deruxtecan monotherapy\n4. Available medical history.\n\nExclusion Criteria:\n\n1. Incomplete medical history.\n2. Pregnancy or breast-breeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}